Newsfile Corp
04 Jul 2026, 21:23 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is alleged to have used channel stuffing to report 20% revenue growth in 2025, while real growth was actually -3%. — Allegations of systemic revenue manipulation and fraudulent growth reporting typically lead to severe valuation collapses and loss of investor trust.
-0.90A federal securities class action lawsuit has been filed against ADMA Biologics alleging false statements, undisclosed related party transactions, and inadequate internal controls. — Formal legal action for securities fraud creates significant contingent liabilities and regulatory risk for the company.
-0.60The stock price of ADMA Biologics declined approximately 29% over two trading days following the release of the Culper Research report. — The immediate price drop confirms a high level of market sensitivity to the fraud allegations.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a federal securities class action lawsuit alleging channel stuffing, undisclosed related party transactions, and misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
